Infectious Disease Control
Hyundai Bioscience Confirms Entry into U.S. FDA Phase 2 Trials for Broad-Spectrum Antiviral 'XAFTY' Following 2026 Biotech Showcase Consensus
- UCSD's Dr. Davey Smith, former ACTIV-2 Protocol Chair, endorses 'Xafty' as "The weapon to end the virus war." - Announces "One Drug, Two Tracks" strategy: Targeting Dengue in Vietnam and Respiratory Viruses (Flu, COVID, RSV) in the U.S. with the same drug. - Dr. Davey Smith: "With this multi-v...
2026-01-15 11:34
1536
Global study targets dengue as disease threatens nearly half the world's population
LISMORE, Australia, Dec. 18, 2025 /PRNewswire/ -- Thousands of dengue forecasting models have been published, but few have been tested in real public-health settings. Now, researchers from the US andAustralia are launching a field evaluation inVietnam to see whether a new early-warning platform c...
2025-12-18 21:01
3376
GC Biopharma Ships First Doses of World's First Recombinant Anthrax Vaccine, 'BARYTHRAX inj.'
- First anthrax vaccine developed using recombinant DNA technology - Annual production capacity of up to 10 million doses at GC Biopharma's facility YONGIN, South Korea, Dec. 8, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a leading global biopharmaceutical company, today announced the first sh...
2025-12-08 14:36
1043
GC Biopharma's Varicella Vaccine Strain 'MAV/06' Listed in WHO Position Paper
* Officially recognized by WHO as a standard varicella vaccine strain alongside Oka * Interchangeability endorsed, enhancing global supply security YONGIN, South Korea, Dec. 2, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a global biopharmaceutical company, today announced that its propriet...
2025-12-02 13:00
1039
Healgen Scientific Spotlights the Rapid Check® COVID-19/Flu A&B Antigen Test to Help Families Stay Prepared for the Respiratory Virus Season
HOUSTON, Nov. 26, 2025 /PRNewswire/ -- As the holiday season approaches, gatherings among family and friends are expected to increase the risk of respiratory virus transmission, including COVID-19 and influenza. In response, Healgen® Scientific highlights the Rapid Check® COVID-19/Flu A&B Antigen ...
2025-11-27 00:00
923
Noul Supplies AI Diagnostic Platform miLab™ to Charité, Europe's Leading University Hospital
* Prestigious Nobel Prize–winning institution confirms adoption of miLab™ following clinical evaluation * "A milestone signaling broader adoption in advanced global healthcare markets" YONGIN, South Korea, Oct. 28, 2025 /PRNewswire/ -- Noul Co., Ltd.(CEO David Lim), an AI-driven blood and can...
2025-10-28 21:00
912
SK bioscience Files for First-in-Human Trial of Universal Coronavirus Vaccine (Pan-sarbecovirus Vaccine) GBP511 Phase 1/2 study in Australia
* Candidate designed to protect against COVID-19 variants and broader Sarbecoviruses * Phase 1/2 study to enroll ~500 healthy adults, with topline results expected by 2028 * We aim to build a universal Sarbecovirus vaccine platform to proactively address future pandemics SEONGNAM, South Kor...
2025-10-15 20:00
1212
GC Biopharma Secures CMO Rights for Shingles Vaccine from Curevo Vaccine
YONGIN, South Korea, Oct. 13, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed an agreement with Curevo Vaccine to secure contract manufacturing (CMO) rights for amezosvatein (development name: CRV-101), a recombinant shin...
2025-10-13 12:38
1150
LakeShore Biopharma Announces Receipt of a Revised Preliminary Non-Binding Proposal to Acquire the Company and Formation of Special Committee
BEIJING, Aug. 28, 2025 /PRNewswire/ -- LakeShore Biopharma Co., Ltd (Nasdaq: LSB) ("LakeShore Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious d...
2025-08-28 20:00
2464
Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System
Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide. FRANKFURT, Germany, Aug. 8, 2025 /PRNewswire/ -- In response to recent outbreaks of Chikungunya fever, Anbio Biotechnology has a...
2025-08-09 09:30
2832
SK bioscience Submits IND for Phase 1/2 Clinical Trial of Adjuvanted Influenza Vaccine Candidate
* Company aims for technology advancement and platform expansion with Korea's first influenza vaccine using an adjuvant * Interim results from the Phase 1/2 trial expected by 2027, aimed at entering the high-immunogenicity vaccine market * "Our SKYCellflu platform with our adjuvanted vaccine...
2025-07-17 19:00
2086
The Voices of Persons Affected by Hansen's Disease Move the World: 3rd Global Forum Held in Bali, Indonesia
TOKYO, July 7, 2025 /PRNewswire/ -- In a landmark gathering that placed lived experience at the center of global health discourse, the 3rd Global Forum of People's Organizations on Hansen's Disease was held inBali, Indonesia, from July 4 to 6, 2025. Organized by the Sasakawa Leprosy (Hansen's Dis...
2025-07-07 19:00
1480
SK bioscience Joins Korea's National Initiative to Develop Avian Influenza Vaccine Amid Rising Pandemic Threats
* Company aims to develop a bird flu vaccine with rapid mass production and variant responsiveness. * SK bioscience and KDCA join forces to build a national pandemic preparedness and response system for potential next-pandemic avian influenza. * "We will promote global public health and grow...
2025-05-06 20:00
2536
MicuRx: 15 Clinical and Preclinical Research Studies to be Presented at ESCMID Global 2025
SHANGHAI, April 8, 2025 /PRNewswire/ -- The 2025 European Congress of Clinical Microbiology and Infectious Diseases (ESCMID Global 2025) will take place in Vienna from April 11 to 15, 2025. As one of the largest, most comprehensive, and influential global academic conferences in the fields of clin...
2025-04-08 15:38
2756
TaiMed Biologics Announces Results from Late-Breaking Phase 2a Data on Long-Acting HIV Maintenance Therapy at CROI 2025
TMB-365/TMB-380 Combination Demonstrates Viral Suspension Without the Need for Susceptibility Screening TaiMed Biologics will reshape HIV treatment management and seeks strategic collaborations with global pharmaceutical partners for the commercialization of its long-acting HIV maintenance thera...
2025-03-18 06:00
1925
SK bioscience Initiates Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
* SK bioscience's first mRNA vaccine candidate enters Phase 1/2 clinical trials inAustralia and New Zealand, with interim results expected by 2026 * Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI * SK bioscience will expand its vaccin...
2025-02-25 21:00
2490
Asieris and CDC Sign Investigational Product Supply Agreement for APL-1202 in Free-Living Amoeba Infections Treatment under Expanded Access Investigational New Drug Program
SHANGHAI, Jan. 6, 2025 /PRNewswire/ -- Asieris Pharmaceuticals (Stock Code: 688176.SH), a leading global biopharmaceutical company dedicated to advancing innovative therapies for genitourinary tumors and women's health with significant unmet medical needs, announced the signing of an investigatio...
2025-01-06 18:05
2064
SK bioscience Receives Approval for Global Clinical Trials of mRNA Japanese Encephalitis Vaccine Candidate
* SK bioscience's first mRNA vaccine candidate is expected to enter clinical trials inAustralia in February 2025, with interim results expected by 2026. * Joint R&D project between SK and CEPI includes up to USD 40 million in initial funding support from CEPI. * SK bioscience will respond to...
2024-12-12 21:00
2733
TVM Capital Healthcare Announces Investment in Human Longevity, Inc. as Part of its Strategy of Supporting Disease Prevention and Healthy Aging
HLI is one of the most established, global longevity science companies and committed to accelerating living to 100+ years of a healthy, active, and mobile life DUBAI, UAE and RIYADH, Saudi Arabia, Sept. 18, 2024 /PRNewswire/ -- TVM Capital Healthcare, an international healthcare expansion and gr...
2024-09-18 16:00
2452
Hyundai Bioscience announces XAFTY®, a groundbreaking broad-spectrum antiviral capable of treating COVID-19, mpox, and dengue
* Hyundai Bioscience presents development updates of its broad-spectrum antiviral at the "Disease Prevention and Control Summit 2024" held in Philadelphia, USA. SEOUL, South Korea, Sept. 11, 2024 /PRNewswire/ -- Dr. Heung-Jeong Woo, a vice president of Hyundai Bioscience shared insights on the...
2024-09-11 14:25
2056
Week's Top Stories
Most Reposted
Visa Supports Chinese Cardholders to Add Cards to Apple Pay for a More Convenient and Secure Payment Experience
[Picked up by 310 media titles]
2026-01-15 13:00Colebrook Bosson Saunders Launches Lana: An Adaptable Laptop Stand Engineered for Hybrid Work
[Picked up by 305 media titles]
2026-01-12 16:16
Ready Server Announces Strategic Expansion into Japan with AT TOKYO Data Centre
[Picked up by 301 media titles]
2026-01-13 13:16
CAYIN AI: Revolutionizing Creativity and Global Communication
[Picked up by 300 media titles]
2026-01-12 16:34
JIOS Aerogel® Secures Hyundai Contract Through New Licensing Model
[Picked up by 299 media titles]
2026-01-15 10:00Most Read
TCL Earns Multiple CES 2026 Awards for Breakthrough Innovations Across TV, Mobile, and Smart Home Categories
2026-01-10 01:00
5469
CATL Opens Middle East's Largest New Energy Aftermarket Facility in Riyadh
2026-01-11 04:10
4364
